Oppenheimer Asset Management Inc. lowered its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 72.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,216 shares of the company's stock after selling 76,319 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Progyny were worth $504,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in shares of Progyny by 341.4% during the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after acquiring an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Progyny by 108.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after acquiring an additional 1,526 shares in the last quarter. KBC Group NV raised its stake in shares of Progyny by 84.6% during the 4th quarter. KBC Group NV now owns 4,669 shares of the company's stock worth $81,000 after acquiring an additional 2,140 shares in the last quarter. Entropy Technologies LP raised its stake in shares of Progyny by 5.5% during the 4th quarter. Entropy Technologies LP now owns 47,883 shares of the company's stock worth $826,000 after acquiring an additional 2,499 shares in the last quarter. Finally, Caitlin John LLC raised its stake in shares of Progyny by 2,974.8% during the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock worth $57,000 after acquiring an additional 3,183 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company's stock.
Insider Buying and Selling at Progyny
In other Progyny news, Chairman David J. Schlanger bought 150,000 shares of Progyny stock in a transaction dated Thursday, December 26th. The stock was acquired at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the transaction, the chairman now directly owns 228,269 shares of the company's stock, valued at approximately $3,350,988.92. This represents a 191.65 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Peter Anevski bought 209,500 shares of Progyny stock in a transaction dated Monday, December 23rd. The stock was acquired at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the transaction, the chief executive officer now directly owns 441,463 shares of the company's stock, valued at approximately $6,392,384.24. The trade was a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently commented on PGNY. Canaccord Genuity Group boosted their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research note on Friday, February 28th. Truist Financial reiterated a "hold" rating and set a $19.00 price objective (down previously from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. JPMorgan Chase & Co. boosted their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Bank of America upped their price target on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Finally, Barclays cut their price target on shares of Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $24.82.
Read Our Latest Stock Analysis on Progyny
Progyny Stock Performance
NASDAQ PGNY traded down $0.25 during mid-day trading on Friday, reaching $20.80. 1,501,046 shares of the stock were exchanged, compared to its average volume of 1,569,894. The business's 50 day moving average is $21.32 and its 200-day moving average is $18.69. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $38.98. The company has a market capitalization of $1.77 billion, a P/E ratio of 35.86, a P/E/G ratio of 2.39 and a beta of 1.41.
Progyny Profile
(
Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Featured Articles
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
